Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.74 |
| ▸ | NT5E | P21589 | 2/20 | 0.57 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.52 |
| ▸ | ADK | P55263 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13296249 | 1.00 | ADORA3 (0.74) | ADORA3NT5EDNMT1LMNAHIF1A | |
| SCHEMBL19837851 | 1.00 | ADORA3 (0.74) | ADORA3NT5EDNMT1LMNAHIF1A | |
| SCHEMBL12912354 | 1.00 | ADORA3 (0.74) | ADORA3NT5EDNMT1LMNAHIF1A | |
| SCHEMBL4452551 | 0.87 | ADORA3 (0.77) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL19843948 | 0.87 | ADORA3 (0.77) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL4452559 | 0.87 | ADORA3 (0.77) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL13769821 | 0.86 | ADORA3 (0.76) | ADORA3NT5EDNMT1LMNAHIF1A | |
| SCHEMBL14364574 | 0.86 | ADORA3 (0.58) | ADORA3ADORA2AADK | |
| SCHEMBL12359596 | 0.86 | ADORA3 (0.58) | ADORA3ADORA2AADK | |
| SCHEMBL14072684 | 0.86 | ADORA3 (0.58) | ADORA3ADORA2AADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158604-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADENOSINE THERAPEUTICS, LLC | 2007-11-22 | — | — | US | disclosed |
| US-7214665-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | ADORA3 7/4885NT5E 67/4885DNMT1 4151/4885 |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885NT5E 67/4885DNMT1 1634/4885 |
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885NT5E 141/4885DNMT1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.